Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Accured Expenses (2023 - 2025)

CG Oncology (CGON) has disclosed Change in Accured Expenses for 3 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 11.77% year-over-year to $3.7 million, compared with a TTM value of $8.7 million through Dec 2025, up 58.28%, and an annual FY2025 reading of $8.7 million, up 58.28% over the prior year.
  • Change in Accured Expenses was $3.7 million for Q4 2025 at CG Oncology, up from -$3.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $7.5 million in Q2 2025 and bottomed at -$4.1 million in Q1 2024.
  • Average Change in Accured Expenses over 3 years is $1.5 million, with a median of $1.6 million recorded in 2023.
  • The sharpest move saw Change in Accured Expenses plummeted 2712.03% in 2024, then skyrocketed 263.53% in 2025.
  • Year by year, Change in Accured Expenses stood at $1.8 million in 2023, then soared by 89.98% to $3.3 million in 2024, then increased by 11.77% to $3.7 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CGON at $3.7 million in Q4 2025, -$3.4 million in Q3 2025, and $7.5 million in Q2 2025.